Prolific Insilico scores up to $200M deal in China; Researchers retract paper on gene involved in CRISPR baby controversy
→ Alex Zhavoronkov’s Hong Kong-based AI-shop Insilico Medicine has been buzzing with the publication of data in Nature, which showed its machine learning approach helped identify potential drugs associated with a particular target in a swift 21 days. On Wednesday, the company disclosed that is has allied with China-based Jiangsu Chia Tai Fenghai Pharmaceutical Co in a deal worth up to $200 million — including an upfront payment, as well as potential milestone and royalty payments.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters